Helsinn Healthcare
Helsinn Healthcare S.A. is a prominent company dedicated to improving the health and quality of life for cancer patients through the development and manufacturing of oncology products. The company specializes in creating active pharmaceutical ingredients and finished dosage forms, focusing on cancer therapeutics, supportive care, and treatments for related conditions such as pain and inflammation. Helsinn is also involved in early-stage investments through its venture capital arm, Helsinn International Services Sarl, which targets innovative technologies in cancer care, metabolic disorders, and gastrointestinal issues. Headquartered in Monaco, with additional offices in Switzerland, Ireland, and China, Helsinn aims to transform new ideas into commercial solutions that significantly enhance the patient experience and address unmet medical needs in oncology and beyond.
iOnctura SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2017. The company focuses on developing innovative therapeutics aimed at modulating immunosuppression within the tumor microenvironment, which is a significant barrier to effective cancer treatment. Its product pipeline includes selective Pi3K inhibitors, Anti-Lag 3 antibodies, ATX inhibitors, Anti-CXCL12 antibodies, and Anti-CD73 antibodies. iOnctura aims to enhance the efficacy of existing immune checkpoint therapies by creating novel drugs that, when used in combination with these therapies, can optimize clinical outcomes for cancer patients. The company has formed partnerships with Merck and Cancer Research Technology, leveraging their resources to advance its preclinical molecules and establish promising combination therapies within cancer immunology. Supported by a distinguished scientific advisory board, iOnctura is well-positioned to innovate in the rapidly evolving field of cancer treatment.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.